Limits...
Report of 12 cases of ankylosing spondylitis patients treated with Tripterygium wilfordii.

Ji W, Li J, Lin Y, Song YN, Zhang M, Ke Y, Ren Y, Deng X, Zhang J, Huang F, Yu D - Clin. Rheumatol. (2010)

Bottom Line: Description of the clinical response of 12 consecutive cases of disease-active ankylosing spondylitis (AS) treated with the herbal medicine Tripterygium wilfordii Hook f (TwHf; lei gong teng, thunder god vine), which has been reported in controlled studies to be effective in rheumatoid arthritis (RA).The clinical status of 12 patients with active AS who were started on 60 mgday(-1) of a commercial tablet preparation of TwHf extract. were monitored at weeks 1, 3, and 6.Until then, this particular report should be considered as case reports and not an endorsement of the use of Tripterygium in clinical practice.

View Article: PubMed Central - PubMed

Affiliation: Department of Rheumatology, Jiangsu Province Hospital of Traditional Chinese Medicine, 155 HanZhong Road, Nanjing, Jiangsu, China, 210029. weiweiji1103@yahoo.com.cn

ABSTRACT

Objective: Description of the clinical response of 12 consecutive cases of disease-active ankylosing spondylitis (AS) treated with the herbal medicine Tripterygium wilfordii Hook f (TwHf; lei gong teng, thunder god vine), which has been reported in controlled studies to be effective in rheumatoid arthritis (RA).

Methods: The clinical status of 12 patients with active AS who were started on 60 mgday(-1) of a commercial tablet preparation of TwHf extract. were monitored at weeks 1, 3, and 6.

Results: Compared to baseline, there was significant improvement in mean values of physician assessment, Bath ankylosing spondylitis disease activity index (BASDAI), Bath ankylosing spondylitis functional index (BASFI), and Bath ankylosing spondylitis global score (BAS-G) at weeks 3 and 6, with no changes in liver enzymes or complete blood count (CBC).

Conclusion: A placebo-controlled double-blind study for Tripterygium is warranted. Until then, this particular report should be considered as case reports and not an endorsement of the use of Tripterygium in clinical practice.

Show MeSH

Related in: MedlinePlus

Changes in parameters in response to Tripterygium. Error bars represent standard deviations. The p values shown are in comparison to corresponding values at week 0. Where p values are not shown, they are more than 0.05. All p values have been corrected for multiple testing. Numbers inside squares represent median values of the corresponding points
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2908750&req=5

Fig2: Changes in parameters in response to Tripterygium. Error bars represent standard deviations. The p values shown are in comparison to corresponding values at week 0. Where p values are not shown, they are more than 0.05. All p values have been corrected for multiple testing. Numbers inside squares represent median values of the corresponding points

Mentions: By week 3 of treatment, the percent of patients showing ASAS20 and ASAS40 response were 91.7% and 33.3%, respectively. These appeared to be sustained to week 6 (Fig. 1). Statistically significant improvement as assessed first by Friedman test (p < 0.001), followed by Wilcoxon signed-rank test, followed by correction for multiple testing was observed with BAS-G, BASDAI, and BASFI starting at week 1 (Fig. 2). For BAS-G and BASDAI, the improvement at week 6 exceeded those at week 3. Statistically significant improvement for physician assessment was observed at weeks 3 and 6. Although there was improvement in BASMI, it was not statistically significant after correction for multiple testing. At week 6, the ESR decreased from 26.8 ± 16.7 at week 0 to 9.8 ± 5.8 (p = 0.007 before Bonferroni correction). The decrease in CRP became statistically significant at week 6 (p = 0.04 after Bonferroni correction; Fig. 2).Fig. 1


Report of 12 cases of ankylosing spondylitis patients treated with Tripterygium wilfordii.

Ji W, Li J, Lin Y, Song YN, Zhang M, Ke Y, Ren Y, Deng X, Zhang J, Huang F, Yu D - Clin. Rheumatol. (2010)

Changes in parameters in response to Tripterygium. Error bars represent standard deviations. The p values shown are in comparison to corresponding values at week 0. Where p values are not shown, they are more than 0.05. All p values have been corrected for multiple testing. Numbers inside squares represent median values of the corresponding points
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2908750&req=5

Fig2: Changes in parameters in response to Tripterygium. Error bars represent standard deviations. The p values shown are in comparison to corresponding values at week 0. Where p values are not shown, they are more than 0.05. All p values have been corrected for multiple testing. Numbers inside squares represent median values of the corresponding points
Mentions: By week 3 of treatment, the percent of patients showing ASAS20 and ASAS40 response were 91.7% and 33.3%, respectively. These appeared to be sustained to week 6 (Fig. 1). Statistically significant improvement as assessed first by Friedman test (p < 0.001), followed by Wilcoxon signed-rank test, followed by correction for multiple testing was observed with BAS-G, BASDAI, and BASFI starting at week 1 (Fig. 2). For BAS-G and BASDAI, the improvement at week 6 exceeded those at week 3. Statistically significant improvement for physician assessment was observed at weeks 3 and 6. Although there was improvement in BASMI, it was not statistically significant after correction for multiple testing. At week 6, the ESR decreased from 26.8 ± 16.7 at week 0 to 9.8 ± 5.8 (p = 0.007 before Bonferroni correction). The decrease in CRP became statistically significant at week 6 (p = 0.04 after Bonferroni correction; Fig. 2).Fig. 1

Bottom Line: Description of the clinical response of 12 consecutive cases of disease-active ankylosing spondylitis (AS) treated with the herbal medicine Tripterygium wilfordii Hook f (TwHf; lei gong teng, thunder god vine), which has been reported in controlled studies to be effective in rheumatoid arthritis (RA).The clinical status of 12 patients with active AS who were started on 60 mgday(-1) of a commercial tablet preparation of TwHf extract. were monitored at weeks 1, 3, and 6.Until then, this particular report should be considered as case reports and not an endorsement of the use of Tripterygium in clinical practice.

View Article: PubMed Central - PubMed

Affiliation: Department of Rheumatology, Jiangsu Province Hospital of Traditional Chinese Medicine, 155 HanZhong Road, Nanjing, Jiangsu, China, 210029. weiweiji1103@yahoo.com.cn

ABSTRACT

Objective: Description of the clinical response of 12 consecutive cases of disease-active ankylosing spondylitis (AS) treated with the herbal medicine Tripterygium wilfordii Hook f (TwHf; lei gong teng, thunder god vine), which has been reported in controlled studies to be effective in rheumatoid arthritis (RA).

Methods: The clinical status of 12 patients with active AS who were started on 60 mgday(-1) of a commercial tablet preparation of TwHf extract. were monitored at weeks 1, 3, and 6.

Results: Compared to baseline, there was significant improvement in mean values of physician assessment, Bath ankylosing spondylitis disease activity index (BASDAI), Bath ankylosing spondylitis functional index (BASFI), and Bath ankylosing spondylitis global score (BAS-G) at weeks 3 and 6, with no changes in liver enzymes or complete blood count (CBC).

Conclusion: A placebo-controlled double-blind study for Tripterygium is warranted. Until then, this particular report should be considered as case reports and not an endorsement of the use of Tripterygium in clinical practice.

Show MeSH
Related in: MedlinePlus